1,008 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by MJP Associates Inc. ADV

MJP Associates Inc. ADV bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel reports. The institutional investor bought 1,008 shares of the medical research company’s stock, valued at approximately $506,000.

Other hedge funds have also recently added to or reduced their stakes in the company. J. Stern & Co. LLP grew its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. BlackRock Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. Norges Bank bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $3,072,744,000. Bank of New York Mellon Corp purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $1,974,561,000. Finally, Auto Owners Insurance Co boosted its position in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after buying an additional 2,423,706 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMO shares. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Piper Sandler upped their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Jefferies Financial Group reissued a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Finally, Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,493 shares of company stock worth $37,657,681 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 2.4%

Shares of Thermo Fisher Scientific stock opened at $628.24 on Friday. The firm has a market cap of $232.29 billion, a PE ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a fifty day moving average price of $539.33 and a 200-day moving average price of $508.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.